All In Biotech

Drug Trial Radar · NCT03788967

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

Last checked: Nov 19, 2026Latest source record: Jul 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,372 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,372

Actual

Start

Jun 3, 2019

Primary completion

May 20, 2020

Study completion May 27, 2020

Sponsor

Lead sponsor
Spero TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The key purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of tebipenem pivoxil hydrobromide (TBPM-PI-HBr) compared to intravenous (IV) ertapenem, in participants with complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP).

Conditions

  • Complicated Urinary Tract Infection
  • Acute Pyelonephritis

Interventions

  • TBPM-PI-HBrDrug

    TBPM-PI-HBr tablets administered orally.

  • ErtapenemDrug

    Antibiotic Therapy for cUTI.

  • Dummy InfusionDrug

    Dummy intravenous infusion.

  • Dummy tabletsDrug

    Dummy tablets orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response (Combined Clinical Cure and Microbiological Eradication) at Test-of-Cure (TOC) in Micro Intent-to-Treat PopulationTime frame: Day 19 (TOC)
  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) in The Safety PopulationTime frame: From the first dose of administration up to Day 25 post-treatment ± 2 days (up to approximately 27 days)

Locations

96 sites in 15 countries. Site status is shown where the registry gives one.

  • Medical Facility

    La Mesa, California

  • Medical Facility

    Miami, Florida

  • Medical Facility

    Blagoevgrad, Bulgaria

  • Medical Facility

    Dobrich, Bulgaria

  • Medical Facility

    Rousse, Bulgaria

  • Medical Facility

    Shumen, Bulgaria

  • Medical Facility

    Sofia, Bulgaria

  • Medical Facility

    Sofia, Bulgaria

  • Medical Facility

    Veliko Tarnovo, Bulgaria

  • Medical Facility

    Karlovy Vary, Czechia

  • Medical Facility

    Liberec, Czechia

  • Medical Facility

    Prague, Czechia

  • Medical Facility

    Ústí nad Labem, Czechia

  • Medical Facility

    Zlín, Czechia

  • Medical Facility

    Kohtla-Järve, Estonia

  • Medical Facility

    Tallinn, Estonia

  • Medical Facility

    Võru, Estonia

  • Medical Facility

    Tbilisi, Georgia

  • Medical Facility

    Tbilisi, Georgia

  • Medical Facility

    Tbilisi, Georgia

  • Medical Facility

    Tbilisi, Georgia

  • Medical Facility

    Zestaponi, Georgia

  • Medical Facility

    Budapest, Hungary

  • Medical Facility

    Budapest, Hungary

  • Medical Facility

    Nagykanizsa, Hungary

  • Medical Facility

    Nyíregyháza, Hungary

  • Medical Facility

    Tatabánya, Hungary

  • Medical Facility

    Riga, Latvia

  • Medical Facility

    Riga, Latvia

  • Medical Facility

    Valmiera, Latvia

  • Medical Facility

    Chisinau, Moldova

  • Medical Facility

    Chisinau, Moldova

  • Medical Facility

    Katowice, Poland

  • Medical Facility

    Krakow, Poland

  • Medical Facility

    Lodz, Poland

  • Medical Facility

    Oświęcim, Poland

  • Medical Facility

    Wroclaw, Poland

  • Medical Facility

    Bucharest, Romania

  • Medical Facility

    Bucharest, Romania

  • Medical Facility

    Bucharest, Romania

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.